Topics:

UPDATED: 2012's Top 10 Diagnostics Companies

Tools

When industry folks look back at 2012, they may well see it as the year that diagnostics companies reached a rock-star-like status in the life sciences industry.

Case in point: Roche's ($RHHBY) failed $6.7 billion bid to acquire Illumina ($ILMN) earlier this year. The hostile bid, initially submitted at $5.7 billion but upped even higher over a tense period of several weeks, showed how a major drug company is serious in developing its molecular diagnostics portfolio, especially now that companion diagnostics are an increasingly important part of the drug development process.

Roche was far from alone, however. Over the last year, many drug companies have either formed or expanded partnerships with diagnostics companies, each with that companion diagnostics goal in clear sight. But diagnostics industry growth moves well beyond this. The healthcare system is changing, with a greater focus on value, reducing errors and giving more quality and cost-effective care. And diagnostics companies are poised to make this happen, with each new advanced test promising to boost the standard of care, speed results and increase accuracy. Diagnostics companies are drawing plenty of venture investment, too. And as the failed Roche/Illumina exercise showed us, diagnostics companies have also become hot acquisition targets because of their desirability in the changing healthcare climate.

With these trends in mind, we asked the folks at EvaluateMedTech to compile a list of the top 10 diagnostics companies in terms of diagnostics sales in 2012. Numbers are currently available through the third quarter. Based on how the numbers are trending, however, estimated results for the year will match or surpass most companies' 2011 sales figures. Roche, the company that made that failed bid for Illumina, places quite high on this list. By the way, it has also recovered nicely from its unsuccessful pursuit of the diagnostics/gene-sequencing darling and has raised its investment substantially in beefing up its own diagnostics arm.

Below is EvaluateMedTech's list of the top diagnostics companies in terms of 2012 sales in 2012. See for yourself how they're growing. And thanks for reading.

-- Mark Hollmer (email | Twitter)

Editor's note: The list below has been corrected to refer to 2012 diagnostics sales figures provided by EvaluateMedtech as estimated rather than year-to-date. Also, the fourth paragraph of the introduction now correctly places the numbers in their proper context. FierceMedicalDevices regrets the error.

bioMerieux

2012 Dx sales (EST): $1.59 billion

2011 Dx sales: $1.63 billion

Sysmex

2012 Dx sales (EST): $1.78 billion

2011 Dx sales: $1.61 billion

Alere ($ALR)

2012 Dx sales (EST): $2.1 billion

2011 Dx sales: $1.8 billion

Johnson & Johnson ($JNJ)

2012 Dx sales (EST): $2.12 billion

2011 Dx sales: $2.16 billion

Becton Dickinson ($BDX)

2012 Dx sales (EST): $2.53 billion

2011 Dx sales: $2.48 billion

  

Thermo Fisher Scientific ($TMO)

2012 Dx sales (EST): $2.9 billion

2011 Dx sales: $2.46 billion

Abbott Laboratories ($ABT)

2012 Dx sales (EST): $4.3 billion

2011 Dx sales: $4.12 billion

Danaher ($DHR)

2012 Dx sales (EST): $4.37 billion

2011 Dx sales: $2.69 billion

Siemens ($SI)

2012 Dx sales (EST): $5.15 billion

2011 Dx sales: $5.11 billion

Roche ($RHHBY)

2012 Dx sales (EST): $7.42 billion

2011 Dx sales: $7.15 billion

 

-- Data compiled by EvaluateMedTech